BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol 2014; 20(24): 7644-7652 [PMID: 24976702 DOI: 10.3748/wjg.v20.i24.7644] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Tan L, Xu SL, Mo ZS, Liu JR, Gan WQ, Chen JH, Gao ZL, Wu ZQ. The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients. Ann Transl Med 2021;9:1431. [PMID: 34733983 DOI: 10.21037/atm-21-3846] [Reference Citation Analysis]
2 Han MS, Park Y, Nah H, Kim HS. Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep/COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients. Ann Lab Med 2017;37:248-53. [PMID: 28224771 DOI: 10.3343/alm.2017.37.3.248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
3 Zhong YW, Di FL, Liu C, Zhang XC, Bi JF, Li YL, Wu SQ, Dong H, Liu LM, He J, Shi YM, Zhang HF, Zhang M. Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection. Clin Microbiol Infect 2016;22:379.e1-8. [PMID: 26577140 DOI: 10.1016/j.cmi.2015.10.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
4 Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti Infect Ther 2019;17:943-55. [PMID: 31738607 DOI: 10.1080/14787210.2019.1694906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG, Johannessen A. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17:438. [PMID: 28629395 DOI: 10.1186/s12879-017-2549-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
6 Yang F, Yu X, Zhou C, Mao R, Zhu M, Zhu H, Ma Z, Mitra B, Zhao G, Huang Y, Guo H, Wang B, Zhang J. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019;15:e1007690. [PMID: 30998767 DOI: 10.1371/journal.ppat.1007690] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
7 Seiz PL, Slanina H, Ziebuhr J, Gerlich WH, Glebe D, Schüttler CG. Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a major role of hepatitis B e antigen expression in disease severity and progression. Int J Med Microbiol 2015;305:663-72. [PMID: 26338147 DOI: 10.1016/j.ijmm.2015.08.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Yan L, Tang X, Zhang Q, Zhu X, Bai L, Du L, Chen E, Tang H. Clinical features of hepatitis B e-antigen positive chronic hepatitis B patients co-existing precore and/or basal core promoter mutations. Future Virology 2018;13:687-95. [DOI: 10.2217/fvl-2018-0091] [Reference Citation Analysis]
9 Voulgaris T, Vlachogiannakos J, Ioannidou P, Papageorgiou MV, Zampeli E, Karagiannakis D, Georgiou A, Papazoglou A, Karamanolis G, Papatheodoridis GV. Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece. Eur J Gastroenterol Hepatol. 2017;29:264-270. [PMID: 27922484 DOI: 10.1097/meg.0000000000000788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Lu Y, Zhou C, Yan R, Lian J, Cai H, Yu J, Chen D, Su X, Qian J, Yang Y, Li L. Dynamic metabolic profiles for HBeAg seroconversion in chronic hepatitis B (CHB) patients by gas chromatography-mass spectrometry (GC-MS). J Pharm Biomed Anal 2021;206:114349. [PMID: 34597840 DOI: 10.1016/j.jpba.2021.114349] [Reference Citation Analysis]
11 Huang Y, Deng H, Peng Z, Huang Y, Long Q, Huang A. Mutations of Basal core promoter and precore regions in hepatitis B virus genotypes B and C. Hepat Mon 2015;15:e23034. [PMID: 25741368 DOI: 10.5812/hepatmon.23034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Giadans CG, Ríos DA, Ameigeiras B, Pietrantonio AM, Lucatelli NL, Haddad L, Mullen E, Heinrich F, De Matteo E, Flichman D, Valva P, Preciado MV. Chronic hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage. J Viral Hepat 2019;26:727-37. [PMID: 30739377 DOI: 10.1111/jvh.13078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol 2014; 20(43): 16037-16052 [PMID: 25473156 DOI: 10.3748/wjg.v20.i43.16037] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
14 El-maadawy EA, Talaat RM, Ahmed MM, El-shenawy SZ. Interleukin-6 promotor gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Human Immunology 2019;80:208-14. [DOI: 10.1016/j.humimm.2018.12.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
15 Mixson-Hayden T, Purdy MA, Ganova-Raeva L, McGovern D, Forbi JC, Kamili S. Evaluation of performance characteristics of hepatitis B e antigen serologic assays. J Clin Virol 2018;109:22-8. [PMID: 30388663 DOI: 10.1016/j.jcv.2018.10.005] [Reference Citation Analysis]
16 Belyhun Y, Liebert UG, Maier M. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia. PLoS One 2018;13:e0191970. [PMID: 29408943 DOI: 10.1371/journal.pone.0191970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Zhai X, Zhu L, Jiang J, Song C, Peng H, Qian J, Zhou M, Zhou Y, Wang Q, Xu J, Wang Z, Liu H, Fan M, Hu Z, Shen H, Zhu F. Virological activity in treatment-naïve HBeAg-negative HBV-infected adult patients: A community-based study in Jiangsu, China. Medicine (Baltimore) 2020;99:e21179. [PMID: 32702877 DOI: 10.1097/MD.0000000000021179] [Reference Citation Analysis]
18 Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zeng DW, Dong J, Zhang JM, Zhu YY, Jiang JJ, Liu YR. HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients. J Med Virol 2015;87:1682-8. [PMID: 25965250 DOI: 10.1002/jmv.24217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Koumbi L, Pollicino T, Raimondo G, Stampoulis D, Khakoo S, Karayiannis P. Hepatitis B virus basal core promoter mutations show lower replication fitness associated with cccDNA acetylation status. Virus Res. 2016;220:150-160. [PMID: 27132039 DOI: 10.1016/j.virusres.2016.04.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
21 Raven SFH, de Heus B, Wong A, Zaaijer HL, van Steenbergen JE. Fluctuation of Viremia in Hepatitis B Virus–Infected Healthcare Workers Performing Exposure-Prone Procedures in the Netherlands. Infect Control Hosp Epidemiol 2016;37:655-60. [DOI: 10.1017/ice.2016.49] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
22 Zhang Q, Cai DC, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl) 2021;134:2810-7. [PMID: 34759219 DOI: 10.1097/CM9.0000000000001793] [Reference Citation Analysis]
23 Ely A, Singh P, Smith TS, Arbuthnot P. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv Drug Deliv Rev 2021;168:134-46. [PMID: 32485207 DOI: 10.1016/j.addr.2020.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
24 Hernández S, Álvarez-Astudillo F, Garrido D, Prieto C, Loyola A, Villanueva RA. Canonical and Divergent N-Terminal HBx Isoform Proteins Unveiled: Characteristics and Roles during HBV Replication. Biomedicines 2021;9:1701. [PMID: 34829930 DOI: 10.3390/biomedicines9111701] [Reference Citation Analysis]
25 Wang XL, Ren JP, Wang XQ, Wang XH, Yang SF, Xiong Y. Mutations in pre-core and basic core promoter regions of hepatitis B virus in chronic hepatitis B patients. World J Gastroenterol 2016; 22(11): 3268-3274 [PMID: 27004005 DOI: 10.3748/wjg.v22.i11.3268] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Zhu L, Zhai X, Wang Q, Jiang J, Peng H, Song C, Ge Z, Qian J, Zhou M, Zhou Y, Xu J, Liu H, Hang D, Hu Z, Shen H, Zhu F. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort. J Viral Hepat 2018;25:1588-98. [DOI: 10.1111/jvh.12978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
27 Candotti D, Diarra B, Bisseye C, Tao I, Pham Quang K, Sanou M, Laperche S, Sanogo R, Allain JP, Simpore J. Molecular characterization of hepatitis B virus in blood donors from Burkina Faso: Prevalence of quasi-subgenotype A3, genotype E, and mixed infections. J Med Virol. 2016;88:2145-2156. [PMID: 27253483 DOI: 10.1002/jmv.24589] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
28 Lee SY, Choi YM, Oh SJ, Yang SB, Lee J, Choe WH, Kook YH, Kim BJ. rt269I Type of Hepatitis B Virus (HBV) Leads to HBV e Antigen Negative Infections and Liver Disease Progression via Mitochondrial Stress Mediated Type I Interferon Production in Chronic Patients With Genotype C Infections. Front Immunol 2019;10:1735. [PMID: 31402915 DOI: 10.3389/fimmu.2019.01735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Portilho MM, Baptista ML, da Silva M, de Sousa PS, Lewis-Ximenez LL, Lampe E, Villar LM. Usefulness of in-house PCR methods for hepatitis B virus DNA detection. J Virol Methods 2015;223:40-4. [PMID: 26215428 DOI: 10.1016/j.jviromet.2015.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sato N, Watanabe S, Miura K, Goka R, Morimoto N, Takaoka Y, Nomoto H, Tsukui M, Isoda N, Nagashima S, Takahashi M, Okamoto H, Yamamoto H. Acute Liver Failure Caused by the Transmission of Hepatitis B Virus from the Spouse after 38 Years of Marriage. Intern Med 2019;58:2963-8. [PMID: 31243227 DOI: 10.2169/internalmedicine.3028-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Lô G, Sow-Sall A, Diop-Ndiaye H, Mandiouba NC, Thiam M, Diop F, Ndiaye O, Gueye SB, Seck SM, Dioura AA, Mbow M, Gaye-Diallo A, Mboup S, Touré-Kâne C. Prevalence of hepatitis B markers in Senegalese HIV-1-infected patients. J Med Virol 2016;88:461-5. [PMID: 26252424 DOI: 10.1002/jmv.24344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]